












































APC: Antigen Presentation Cell  
APL: Altered Peptide Ligand 
BBB: Blood-Brain Barrier 
BDCA-1/3: Blood Dendritic Cell Antigen -1/3 
CCL2: Chemokine C-C ligand-2 
CLEC-2: C-Lecitin receptor-2 
CNS: Central Nervous System  
CCR6: Chemokine Receptor 6 
CSF: Cerebrospinal Fluid 
DAMP: Damage-Associated Molecular Pattern 
DC: Dendritic Cell 
DMT: Disease-Modifying Therapy  
EAE: Experimental Autoimmune Encephalomyelitis 
EMA: European Medicines Agency 
FDA: Food and Drug Administration  
Foxp3: Forkead box protein 3 
GAEM: Grupo de Afectados de Esclerosis Múltiple 
GAL9: Galectin-9 
GM-CSF: Granulocyte-Macrophage Colony-Stimulating Factor 
GMP: Good Manufacturing Practice 
HLA DR: Human Leukocyte Antigen-antigen D Related  
HO-1: Heme Oxygenase-1 
iDC: immature Dendritic Cell 
IDO: Indoleamine 2,3-Dioxygenase 
ILT-3/4: Ig-Like Transcripts-3/4 
LC: Langerhans Cell  
LPS: Lipopolysaccharide  
MBP: Myelin Basic Protein 
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mDC: myeloid Dendritic Cell 
MMP-2/-9: Matrix Metalloproteinase-2/-9 
MHC-II: Major Histocompatibility Class-II 
MRI: Magnetic Resonance Imaging 
MS: Multiple Sclerosis 
MoDC: Monocyte-derived Dendritic Cell 
MOG: Myelin Oligodendrocyte Glycoprotein  
NFAT: Nuclear Factor of Activated T-cell 
NLR: Nucleotide Like Receptor  
NMSS: National Multiple Sclerosis Society  
1,25(OH)2D3: 1,25-dihydroxyvitamin D3 
PAMP: Pathogen-Associated Molecular Pattern 
PBMC: Peripheral Blood Monocyte Cells 
pDC: plasmacytoid Dendritic Cell  
PD-L1: Programmed Death-Ligand 1 
PLP: Proteolipid Protein 
PPMS: Primary Progressive Multiple Sclerosis 
RNS: Reactive Nitrogen Species  
ROS: Reactive Oxygen Species 
RRMS: Relapsing-Remitting Multiple Sclerosis  
SPMS: Secondary Progressive Multiple Sclerosis 
TCR: T-Cell Receptor  
TLR: Toll-Like Receptor 
Tol-DC: Tolerogenic Dendritic Cell 
TRAIL: TNF-Related Apoptosis-Inducing Ligand 
VDR: Vitamin D Receptor 
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1. Abstract 
Multiple sclerosis (MS) is a multifactorial disease characterized by immune 
dysregulation, neurodegeneration, and failure of the central nervous system (CNS) 
repair mechanisms. Identifying specific myelin-derived peptides as important targets of 
the autoreactive immune response has opened the possibility to develop antigen-specific 
therapeutic approaches. Dendritic cells (DCs) are the most potent professional antigen-
presenting cells (APCs) of the immune system capable of inducing or suppressing the 
T cell response, their effect depends on different factors such as the degree of maturity, 
signals obtained from the local microenvironment, communication with other immune 
cells or the DCs subtype. Therefore, DCs have proved to be one of the most promising 
tools in immunotherapy in order to modify the immune response and restructure 
immune tolerance. There are some established protocols in vitro for generating 
monocyte-derived tolerogenic-DCs (tol-DCs) that exhibit numerous 
immunosuppressive mechanisms. However, the therapeutic potential of DCs has not yet 
been fully exploited clinically. In this report, I describe the immunopathogenesis of MS, 
different subsets of DCs, the central role of DCs in the initiation of antigen-specific 
tolerance, and protocols for generating tol-DCs. In addition, I will discuss the 
characterization of tol-DCs for clinical application, as well as recent clinical trials based 
on tol-DCs to treat MS.  
 
 
Terapia Celular Antígeno-Específica: Células Dendríticas Tolerogénicas Cargadas 
con Péptidos de Mielina para la Esclerosis Múltiple 
La esclerosis múltiple (EM) es una enfermedad multifactorial caracterizada por la 
desregulación inmune, la neurodegeneración y la alteración de los mecanismos de 
reparación del sistema nervioso central (SNC). Después de identificar los péptidos 
derivados de mielina específicos como importantes dianas en la respuesta autoinmune, 
se abrió la posibilidad de desarrollar aproximaciones terapéuticas antígeno-
específicas. Las células dendríticas (CDs) son las células presentadoras de antígeno 
más potentes del sistema inmune capaces de inducir o suprimir la respuesta de células 
T, su efecto depende de varios factores como el grado de madurez, las señales obtenidas 
del microambiente local, la comunicación con otras células inmunes o el subtipo de CD 
al que pertenecen. Por eso, las CDs han resultado ser una de las herramientas más 
prometedoras en la inmunoterapia con el objetivo de modificar la respuesta inmune y 
reestructurar la tolerancia inmune. Hay varios protocolos in vitro establecidos para 
generar CDs tolerogénicas (tol-CDs) derivadas de monocitos y estables que exhiben 
numerosos mecanismos inmunosupresores. Sin embargo, aún no se ha explotado por 
completo el potencial terapéutico de las CDs en clínica. En este proyecto, describiré la 
inmunopatogenia de la EM, los diferentes subtipos de CDs, el papel central de las CDs 
en el inicio de tolerancia específica de antígeno y los protocolos de generación de tol-
CDs. Además, discutiré la caracterización de las tol-CDs para la aplicación clínica, así 
como los recientes ensayos clínicos basados en tol-CDs para tratar la EM.  
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2. Integration of three fields  
This project has been developed to integrate three different fields related to the 
Pharmacy degree: Immunology, as the main discipline and Physiology and 
Pathophysiology, and Pharmacology and Therapeutics, as secondary scopes.  
The principal field is Immunology due to this work is focused on investigating how a 
group of immune system cells of a patient who suffers from MS can become a therapeutic 
strategy to modify the course of disease. To do so, an exploration of the DCs function and 
classification has been made, making a clear distinction between immunogenic DCs and 
tol-DCs. Moreover, this subject has been critical to understanding the immune 
dysregulation that develops in MS.  
Physiology and Pathophysiology has been integrated into the development of this project 
at the beginning of this work when an overview of the most relevant characteristics of 
MS, in terms of diagnosis and clinical manifestations, is made. This scope has also been 
useful for explaining the pathophysiological process leading to MS.  
Finally, Pharmacology and Therapeutics has been present when a brief description has 
been made of the pharmacological therapies currently applied in individuals with MS. 
Furthermore, at the end of the work, not only is the antigen-specific therapy discussed 
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3. Introduction: Multiple Sclerosis 
 
MS is an autoimmune disease in the CNS that is characterized by loss of motor and 
sensory functions, that results from immune-mediated inflammation, demyelination and 
subsequent axonal and neuronal degeneration. (1) 
3.1. Prevalence and Aetiology  
 
MS is one of the most frequent neurological diseases with 2.5 million affected 
people worldwide and the second cause of disability in people between 20 and 40 years 
old (2,3). It has three times more incidence in woman than in men, and in northern 
locations (3,4). Besides, MS is considered to be a multifactorial disease, involving genetic 
susceptibility and environmental factors such as viral pathogens, smoking, chemicals, diet 
and vitamin D levels (5).  
 
3.2. Diagnosis and Clinical Manifestations 
 
The clinical diagnosis is developed through medical history, neurological 
examination and various tests that allow identifying demyelinating lesions such as 
Magnetic Resonance Imaging (MRI) and cerebrospinal fluid (CSF) analysis. According 
to the criteria, to diagnose MS, the neurologist must find evidence of damage in at least 
two separate areas of the CNS, that the damage occurred at different points in time and 
rule out other neurological diseases. (6,7) 
 
The range of clinical manifestations of MS is variable and the evolutionary course is 
highly unpredictable due to various pathogenic mechanisms. The most frequent 
symptoms of MS correspond to deficiencies: movement, sensitivity, vision, coordination 
and balance, pain and fatigue, cognitive and psycho-emotional functions, among others.  
The symptoms that MS patients report early are fatigue, double or blurred vision, 
weakness, loss of strength, difficulty walking, numbness or tingling. Finally, due to the 
diversity in the presentation of symptoms, as well as their frequency and intensity, it is 
considered that there is no typical MS. (6,8) 
 
3.3. Three Types of MS  
 
Three basic MS disease courses (also called types or phenotypes) have been defined 
(6): 
 
§ Relapsing-remitting MS (RRMS): it is characterized by an initial episode of 
neurological dysfunction (clinically isolated syndrome). It is also distinguished by 
attacks (relapses or exacerbations) due to the occurrence of symptoms of neurologic 
dysfunction for more than 24 hours. Focal CNS inflammation correlate with 
relapses and demyelination are appreciable as white matter lesions, using MRI. 
These attacks are followed by periods of partial or complete recovery (remissions) 
(See Figure 1: black line). During remissions, all symptoms may disappear, or some 
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symptoms may continue and become permanent. However, during periods of 
remission, there is no apparent disease progression. It affects 85% of people at the 
time of diagnosis (1,2,6,9).  
 
§ Secondary progressive MS (SPMS): approximately 50% of those affected by 
RRMS may refer to SPMS about 15 years after diagnosis.  SPMS is characterized 
by a progressive worsening of neurologic function (accumulation of disability) over 
time (6,9). Progressive neurological declines is caused by CNS atrophy; that is, 
increased axonal loss and decreased brain volume (See Figure 1: red lines) (2). 
 
§ Primary progressive MS (PPMS): characterized by worsening neurologic 
function from the onset of symptoms and absence of early relapses or remissions 





















3.4. Treatment Overview 
 Treatments used in MS have different objectives (6,8,10): 
P Modify the natural course of the disease.  
P Treat relapses, exacerbations or attacks.  
P Alleviate the presence of symptoms.  
Figure 1. Progression over time and disability levels of the different stages of MS (2).  
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In this review we summarize the most relevant disease-modifying therapies (DMT) 
approved by the Food and Drug Administration (FDA): 
1. The immunomodulators (Interferon-β (IFN-β), Glatiramer acetate, Dimethyl 
fumarate and Teriflunomide) whose mechanism of action is to downregulate 
cytokines and chemokines production in the inflammatory cascade, thereby 
inhibiting T cells activation and migration through the blood-brain barrier (BBB) 
and their arrival in the CNS (5). This group represents the first-line therapy (4).  
 
2. The general immunosuppressant (Mitoxantrone) that interfere with DNA repair 
causing nucleotide crosslinking and DNA strand breaks. It inhibits lymphocytes 
and monocytes migration, B cells function, and secretion of Tumor Necrosis 
Factor-α (TNF-α), Interleukin-2 (IL-2) and Interferon-γ (IFN-γ). (11) 
 
3.  Immune - selective intervention (11): 
 
a. Blockade (Natalizumab): humanized monoclonal antibody against the α4 
subunit of VLA-4 integrin. This antibody blocks the binding between VLA-4 
and VCAM-1 and fibronectin, preventing B cells and T cells migration into the 
CNS.  
 
b. Sequestering (Fingolimod): its target is the sphingosine-1-phosphate receptor. 
It works sequestering lymphocytes in lymph nodes by inhibiting lymphocyte 
egress. Furthermore, it inhibits the entry of DCs into secondary lymphoid 
organs.  
Both previous drugs represent the second-line therapy (4).  
c. Depleting (Alemtuzumab): humanized monoclonal antibody against a cluster 
of differentiation (CD)52 on T and B cells. This antibody leads to depletion of 
T and B cells expressing the CD52 marker, while regulatory T (Treg) cells are 
maintained due to their low expression of CD52.  
 
d. Decreased signaling (Daclizumab): humanized antibody against CD25, IL-2 
receptor. It prevents the signaling of IL-2 and increases CD56+ NK cell activity 
(11). The European Medicines Agency (EMA) has withdrawn it from the 
market after detecting cases of severe inflammatory brain disorders, including 
encephalitis and meningoencephalitis (12). 
 
e. Decreased presentation (Ocrelizumab): humanized antibody against CD20+ 
B cells. Thus, it depletes CD20+ B cells and reduces pathogenic B cell antigen 
presentation. 
 
f. Apoptosis (Cladribine): its target is adenosine deaminase. It involves immune 
cells depletion by induction of lymphocyte apoptosis. It also reduces CD4+ T 
cells and CD8+ T cells and B cells.  
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IFN-β: Interferon-beta; MS: Multiple Sclerosis; DMTs: Disease-Modifying Therapies  
 
Many of these treatments involve general immunosuppression, which entails 
numerous adverse side effects (such as multifocal progressive leukoencephalopathy), 
they are partially effective, and especially in the initial stages (9,11). For this reason, there 
is a need to investigate safer treatments capable of stopping or delaying the progression 
of disability caused by MS.  
 
In this review, we focus on a specific treatment with human tol-DCs loaded with myelin 




The main objective of this project is to carry out a comprehensive bibliographic 
research on one of the most promising immune-based therapies: tol-DCs loaded with 
myelin-derived peptides as a therapeutic tool for MS. So far, DCs have been investigated 
in several clinical trials to promote an immune response against infectious diseases or 
cancer. However, very few clinical studies have exploited their specific 
immunosuppressive potential.  
For this reason, the main goal of this work is to know the immunosuppressive mechanism 
by which tol-DCs may represent a novel therapeutic strategy for MS. The secondary 
objectives, closely linked to the main one, are the following:  
P Study the immunopathological mechanisms that lead to MS.  
P Investigate which are the different protocols established to generate tol-DCs in vitro  
applied in clinical trials.  
P Analyse the entire procedure from peripheral blood monocyte cells (PBMCs) are 
obtained, through the isolation and treatment of monocytes, until myelin-peptides 
loaded tol-DCs are administered to MS patients.  
Therapeutic position Drug  Administration route Indication 
First-line therapy IFN-β Intramuscular or 
subcutaneous 
Relapsing forms of MS 
Glatiramer acetate Subcutaneous Relapsing forms of MS 
Dimethyl-fumarate Oral Relapsing forms of MS 
Teriflunomide Oral Relapsing forms of MS 
Second-line therapy Fingolimod Oral Relapsing forms of MS 
Natalizumab Intravenous Relapsing forms of MS 
In assignment 
process 
Alemtuzumab Intravenous Relapsing forms of MS who had 
an inadequate response to ≥2 
previous DMTs 
Cladribine Oral Relapsing forms of MS 
Ocrelizumab Intravenous Relapsing or primary progressive 
MS 
Table 1. Therapeutic position, administration route and indications for FDA-Approved DMT for MS (7,10). 
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P Know if the clinical trials conducted so far have proved safe, well-tolerated and 
clinical effectiveness by MS patients.  
P Make an overview of immunotherapies with a similar strategic approach followed 
by the tol-DCs that are currently underway. 
 
5. Methods and Material 
This project belongs to the bibliographic research category. The compilation of 
information to conduct this project has involved databases such as PubMed, Scopus or 
Google Scholar to search for bibliographic articles, clinical trials and reviews in 
recognized journals like Frontiers in Immunology. The selected material was filtered 
based on the number of citations in which those articles have been mentioned, publication 
date and journal impact factor, giving preference to those that have been reported more 
recently and a high number of citations.  The keywords for precise search were: 
(“Multiple Sclerosis” [AND] “Tolerogenic Dendritic Cells”) and (“Multiple Sclerosis” 
[AND] “EAE” [OR] “Experimental Animal Encephalomyelitis”). 
Besides consulting the previous sources, information has also been obtained from web 
pages related to the field of inquiry. It is the case of the website “MS online” 
corresponding to the Grupo de Afectados de Esclerosis Múltiple (GAEM) Foundation, 
National Multiple Sclerosis Society (NMSS), and Food and Drug Administration (FDA). 
Finally, Medline Plus has served as a medical encyclopaedia that has resolved doubts 




6.1. The Pathophysiology of MS 
The pathology of MS is characterized by the presence of plaques or lesions, 
demyelinated areas of white and grey matter of the brain and spinal cord, that demonstrate 
a loss of myelin sheaths and oligodendrocytes. While axons and neurons are preserved in 
early disease, gradual neuroaxonal loss occurs in advance disease, correlating with the 
disability degree of individuals with MS. (2,13) 
 
6.1.1. Early Stages 
The inflammation process occurs at all stages of MS, but it is less prominent in 
the remissions phases than in the relapses phases. In the early stages, the brain and spinal 
cord show little damage in areas outside of focal lesions (also called normal-appearing 
white matter). However, general brain atrophy has been contemplated. These early 
lesions are characterized by infiltrated peripheral immune cells such as macrophages, T 
CD8+ cells, T CD4+ cells, B cells and plasma cells and leakage of the BBB. (2,14) 
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6.1.2. Advanced Stages  
As the disease progresses, microglial and astrocyte activation, myelin loss, 
axonal injury, and inflammatory T-cell and B-cell are evident. As a result, even more 
pronounced atrophy of grey and white matter (13). About the inflammatory infiltration, 
the proportion of B cells and plasma cells increases, but the composition of T cells does 
not differ (15). Note that, throughout the course of the disease, microglia and 
macrophages remain in a chronic state of activation (16). 
 
6.1.3. Progressive Stages 
CNS inflammation is characterized by a low proportion of invasive peripheral 
cells in the lesions. Studies have shown that SPMS can present tertiary lymphoid 
structures, that is, inflammatory aggregates in the meninges which could help tissue 
injury and cortical demyelination. (17) 
Two mechanisms can be distinguished by which neurodegeneration and axonal atrophy 
are caused. The first mechanism is immune-dependent and is characterized by the 
performance of the immune cells resident in the CNS, also involving microglia, 
astrocytes, and potentially B cells from ectopic germinal centers. The second 
mechanism is immune-independent and diverse events take place: mitochondrial injury 
due to the mitochondrial DNA mutation and the reduction of the respiratory chain 
activity, resulting in neuronal energy deficit, owing to the enhanced production of 
reactive oxygen species (ROS) and reactive nitrogen species (RNS); oxidative stress 
enhanced by iron (Fe3+) release from active demyelination areas; ionic imbalance due 
to glutamate excitotoxicity causing a massive influx of calcium into neurons. (11)  
 Figure 2. Both immune dependent and independent mechanisms in progressive MS (11). 
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6.2.  The Immunopathogenesis of MS 
Immune dysregulation affects both innate and adaptative immunity (5). 
6.2.1. The Role of Effector CD4+ T Cells, Microglia and Macrophages 
The immunological cascade begins when an antigen binds to peripheral DC 
receptor. This DC processes the antigen and communicated it to the naïve CD4+ T cell 
into the lymph node. The adaptative immune response is activated. (5) 
DCs have an activated phenotype through expression of the cell surface marker CD83. 
Once activated, DCs induce differentiation of T helper 1 (Th1) and T helper 17 (Th17) 
cells. The differentiation occurs based on the cytokines that Antigen Presentation Cells 
(APCs) secrete; in the presence of IL-12, naïve CD4+ T cells differentiate into Th1 cells, 
secretors of IFN-γ and TNF-α. Whereas in the presence of Interleukin-23 (IL-23), naïve 
CD4+ T cells differentiate into Th17 cells, secretors of IL-17, IL-21, IL-22 and IFN- γ. 
Studies reveal individuals with MS experience increased Th17 cells in peripheral blood 
during acute relapse. (5,11) 
Different mechanisms of pathogenicity of Th17 cells are involved in MS. On the one 
hand, they produce matrix metalloproteinase (MMP-2 and MMP-9) and ROS that 
contribute to the increase of BBB permeability (18,19). Furthermore, these cells are 
involved in the formation of ectopic lymphoid follicles. Finally, Th17 cells produce 
granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF promotes the 
continuity of inflammation by mobilizing bone marrow-derived monocytes and CD103+ 
DC, and by upregulating major histocompatibility complex class II (MHC II) and 
cytokines in APCs (5,20). 
Pro-inflammatory cells migrate, cross the BBB to the CNS, these are reactivated locally 
in response to CNS autoantigens presented by APCs, leading to an inflammatory 
response. Pro-inflammatory cytokines activate macrophages (infiltrated cells into CNS in 
response to injury) and microglia (resident CNS cells derived from myeloid progenitors) 
which, in turn, produce other pro-inflammatory mediators such as TNF-α, ROS and RNS, 
ultimately responsible for demyelination and axonal loss. So, microglia and macrophages. 
play a crucial role in the process of inflammatory attack on myelin antigens. (5,21) 
It has been observed in animal models that Th1 and Th17 cells produce different diseases 
in consonance with immunophenotype. A predominant Th1 cells response involves 
infiltration mainly into the white matter of meningeal and parenchymal mononuclear 
cells. In contrast, a predominant Th17 cells response facilitate the formation of ectopic 
lymphoid follicles in the meninges (22). Also, it has been demonstrated that a 
predominant Th1 cells response localizes the pathogenic cells infiltration mainly in the 
spinal cord, whereas the predominant Th17 cell response, in the brain (23). 
6.2.2. The Role of Effector CD8+ T Cells  
CD8+ T cells are also involved in the pathophysiology of MS. It has been found 
that CD8+ T cells express CD161 and chemokine receptor 6 (CCR6) and penetrate the 
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BBB through α-4 subunit of VLA-4 integrin binding. CD8+ T cells secrete pro-
inflammatory mediators such as IL-17, IFN-γ and can also release cytolytic granules 
causing axonal damage. Moreover, the characteristic relapses in some stages of MS could 
be related to the loss of terminally differentiated of autoregulatory CD8+ T cells. (5,11) 
 
6.2.3. The Role of γδ Cells 
The γδ cells are a subpopulation of T cells. During the early stages of the disease, 
these cells can be found in large amount in the CSF. δγ cells have been characterized by 
being CD161+ CCR6 + and secreting IL-17. Activation of these cells can boost responses 
effector T cells under the effect of IL-23 and deprived of the activity of Treg cells. This 
process further promotes autoimmunity. (5) 
 
6.2.4. The Role of B Cells 
B cells are involved in MS immunopathogenesis in different ways. First, these 
cells are capable of activating effector CD4+ T cells by binding between MHC class II of 
B cell and T cell receptor (TCR) of T cells. T cells contribute in the proliferation and 
differentiation of B cells. Second, regulatory B cells (B reg) can inhibit effector T cells 
by secreting IL-10, IL-35, transforming growth factor-β (TGF-β), and programmed 
death-ligand 1 (PD-L1). In MS patient, the regulatory function of B cells is defective and 
instead, they have a deposit of autoreactive B cells. Third, B cells can differentiate into 
plasma cells to produce autoantibodies, both in the periphery and in the CNS. These 
autoantibodies are directed against myelin antigens and other components of CNS. 
Fourth, B cells can pass through the BBB and collaborate in ectopic germinal centers 
formation. Ectopic lymph nodes in the CNS are compartmentalized and operate 
independently to lymph nodes located on the periphery.  Last but not least, B cells secrete 
pro-inflammatory cytokines such as TNF-α, GM-CSF and IL-6 which activate microglia 
and astrocytes. (11) 
Within CSF, memory B cells can differentiate into plasmablasts causing oligoclonal 
bands (24). The presence of oligoclonal bands is correlated with a progressive clinical 
course of the disease. As discussed in the introduction, one of the methods for diagnosing 
MS is by observing oligoclonal bands in CSF analysis. However, CSF analysis alone 
cannot confirm or exclude a diagnosis of MS because these abnormalities can also be 
found in other neurological diseases (5,6). 
 
6.2.5. The Role of Astrocytes 
Astrocytes are responsible for controlling the infiltration of peripheral pro-
inflammatory leukocytes through the BBB and regulating oligodendrocytes, microglia 
and cells of the adaptive immune system.  A study has reported that elevated clusters of 
astrocytes enzyme B4GALT6 have been found in lesions of brain promoting 
inflammation and neurodegeneration during chronic CNS inflammation. (5) 
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6.2.6. The Role of Regulatory and Natural Killer Cells 
In the immunopathology of MS also fits involving regulatory cells capable of 
modulating immune activation and thus, control the development of autoimmunity. 
Several subsets of regulatory CD4+ T cells have been identified, but among the most 
prominent Treg are those that express the transcriptor factor Forkhead box protein 3 
(FoxP3) and inhibitory immune checkpoint surface molecules that facilitate the 
suppression of T cells proliferation. Another main regulatory CD4+ T cells is the Tr1 
regulatory CD4+ T cell able to inhibit cell proliferation via the secretion of IL-10. Natural 
Killer cells (NK cells), through their ability to kill activated and pathogenic CD4+ T cell, 
















6.3.  DCs as a New Target for MS Treatment 
 
Dendritic cells are the most potent antigen-presenting cells that exist and they are 
characterized by regulating both immune and tolerogenic responses depending on the 
context in which the interaction between the antigen and DCs occurs. (25) 
 
The rationale for working with DC in antigen-specific cell therapy approach is its 
functional plasticity, its property of generating highly specific immune responses and the 
possibility of obtaining DC in vitro under suitable conditions for clinical applications 
(25). In addition, the results obtained in experimental animals models suggest tol-DCs 
treatment could represent a therapeutic tool for autoimmune diseases such as MS (26).  
 
Figure 3. Effector T cells and B cells involved in MS immunopathogenesis (11). 
Antigen-Specific Therapy with Tol-DC for MS | Paula Vargas Durán 
 - 10 - 
6.3.1. DCs Activation 
Immature DCs (iDCs) are found in peripheral tissues where they patrol and absorb 
large amounts of membrane-bound or soluble antigens by micropinocytosis and 
phagocytosis. Along these lines, iDCs acquire pathogen-associated molecular patterns 
(PAMPs) and damage-associated molecular patterns (DAMPs) in situ through a set of 
surface and intracellular receptors, such as cell surface-C-type lectins, surface and 

















Once they interact with a pathogen, iDCs undergo phenotypic and functional 
transformations, through a process called maturation (25). Maturation implicates that 
antigens-loaded iDCs migrate into the draining lymph nodes via afferent lymphatics 
where they lose the ability to phagocytose antigens and acquire stimulatory properties to 
present antigens to T cells. Antigen presentation and T cells differentiation requires 
increased expression of surface MHC class II molecules to be recognized by T-cell 
receptor (TCR) on T lymphocytes and increased expression of costimulatory molecules 
associated with the ability to promote or suppress T cells through different signaling axes: 
CD80/CD86-CD28, CD40-CD40L, OX40L-OX40, ICOSL-ICOS and galectin (GAL)9-
TIM3, CD80-CTLA4, PDL1-PD1, PDL2-PD1, respectively (see Figure 4); as well as 
enhanced production of pro-/anti-inflammatory cytokines and chemokines. This process 
leads to the development of an immune response T cell subsets (4,27,28). 
Figure 4. Different signals involved in the induction of T-cell mediated immunity or tolerance by DCs. 
Signal (1) Antigen presentation. Modulation of T cell activity occurs by the presentation on MHC I 
and MHC II molecules. Signals (2) and (3) Co-stimulatory molecules [belonging to the B7 and TNF 
protein families] and soluble cytokines can prime T cell response (green arrows and receptors). 
Contrarily, CTLA4: cytotoxic T lymphocyte antigen 4; PD1: programmed cell death protein 1; PD-
L1: programmed cell death-1 ligand and TIM-3: T cell immunoglobulin and mucin-domain 
containing-3 and soluble factors such as IL-10 can suppress T cell activation (red arrows and 
receptors). (28) 
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6.3.2. Human DCs Subpopulations 
DCs comprise a heterogeneous population of bone-marrow-derived cells that are 
founded in spleen, blood, skin and non-lymphoid tissues. Five main DCs subtypes have 
been distinguished (4,28,29):  
§ Myeloid DC (mDC): mDCs are resident in lymphatic tissue and are also present in 
the blood, peripheral tissues and lymph nodes, where they constantly uptake blood 
or tissue antigens. Regarding their role in autoimmune diseases, they are implicated 
in their progression by increased pro-inflammatory cytokines production and T cell 
activation.  
o Type 1 conventional DC (cDC1): correspond to the CD141+/blood DC antigen 
(BDCA)-3. 
- Main surface markers: CD11clow, HLA-DR+, DEC205+, XCR1+.  
- cDC1 are characterized by their efficient antigen cross-presentation and CD8+ 
and Th1 cells priming. Due to the excellent processing and cross-presentation 
of exogenous antigens on MHC class I molecules to activate CD8+ T cells 
and prime Th1 response, cDC1s gain a unique potential to induce immunity 
against intracellular pathogens and malignant cells.  
 
o Type 2 conventional DC (cDC2): correspond to the CD1c+ /BDCA-1. 
- Main surface markers: CD11c+, C11b+, HLA-DR+, CD172a+.  
- cDC2s are defined by several functions such as CD4+ T cells priming, Th17 
activation, Th1 and Th2 response induction and Treg cells activation. They 
present peptides on MHC class II molecules to CD4+ T cells.   
 
§ Plasmacytoid DC (pDC): pDCs are a small subset of DCs which concentrate mainly 
in lymph tissues and blood and they access the lymph nodes through the blood 
circulation. About their participation in autoimmune diseases, they are implicated in 
their progression by increasing IFN-α production and decreasing ability to prime 
Treg cells.  
- Main surface markers: CD11c-, CD123+, CD303+, CD304+, chemokine 
receptor (CCR)2+, CXC-Chemokine receptor (CXCR)3+, HLA-DRlow.  
- Their main function is antiviral immunity, upon foreign nucleic acid, they 
start to produce IFN type I. They are also characterized by their poor ability 
to prime naïve T cells. pDC present peptides only after cell activation. 
However, at steady state pDCs can impulse T cell anergy and promote Treg 
cells development, thus they can also induce tolerogenic immune responses. 
 
§ Langerhans cell (LC): resident in the epidermis. Its role in autoimmune diseases is 
not yet well-defined.  
- Main surface markers: Langerin, Epcam, BDCA1+, CD1a+, CD11chigh. 
- LCs participate in immunological surveillance. LCs are responsible for 
maintaining the tolerance towards commensals skin agents while retaining 
the selective ability to respond to certain pathogens. 
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§ Monocyte-derived DC (MoDC): MoDCs are mainly differentiated from monocyte 
in peripheral tissues during inflammation. 
- Main surface markers: CD11c+, CD11b+, HLA-DR+, CD1c+, CD206+, 
CD209+, CD1a+, CD172a+, CCR2+.  
- MoDCs induce context-dependent differentiation of CD4+ T cells toward a 
Th1, Th2 or Th17 phenotype. 
To summarize, from all DCs subsets above mentioned, the cells have been described to 
generate both immunological and suppressive function are cDC2, pDCs, LCs and 
MoDCs.  
 
6.3.3. Immunogenic DCs 
iDCs act as sentinels that detect pathogens by membrane-bound TLR or through 
nucleotide-binding oligomerization domain-like receptors (NLR) within cytosol, for that 
reason they populate almost all surfaces of the body. They use proteolytic machinery 
(endolysosomal and proteasomal) through which they partially degrade the antigens to 
peptides. After encountering exogenous antigens and appropriate signals, iDCs 
differentiate into mature DCs, which are characterized by upregulation of MHC class I 
and II molecules and costimulatory molecules and responsiveness to inflammatory 
chemokines. Mature antigen-loaded DCs drive differentiation and activation of T cells, 
by providing immunomodulatory signals through cell-cell contact and pro-inflammatory 
cytokines, into effector T cells with specific functions and cytokines profiles. Although 
several cells of the immune system such as B cells or macrophages also have the property 
of presenting antigens, DCs differ because they have the unique ability to activate naïve 













Figure 5. Dendritic cells (DCs) can polarize 
immune response through stimulate both 
pro- and anti-inflammatory activities in 
response to different signals. TLR: Toll-
Like Receptors, HSP: Heat Shock Proteins 
(4).  
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The full activation of naïve T cells requires a three-step signaling process (27,30): 
1. The binding of the TCR to its cognate antigen presented in MHC molecules by 
DCs.  
2. The binding of CD28 with co-stimulatory molecules like members of the B7 
protein family CD80 and CD86. 
3. The interaction of pro-inflammatory cytokines secreted by DCs with the 
respective cytokine receptors.  
 
6.3.4. Tolerogenic DCs  
iDCs can present self-antigens to T cells in the thymus to maintain immunological 
tolerance through clonal T cell deletion, induction of T cell anergy, inhibition memory 
and effector T cell responses, and generation or the differentiation of CD4+ CD25+Foxp3+ 
Treg cells. For this reason, they are essential in maintaining central and peripheral 
tolerance. (27,28)  
Regarding the phenotypic characteristics of tol-DCs, they show an immature or semi-
mature phenotype distinguished by the low amount of surface MHC and co-stimulatory 
molecules such as CD80 and CD86 (31). The activation of anergy-associated genes under 
the control of nuclear factor of activated T-cell (NFAT) and induction of T cell anergy 
are the consequence of antigen presentation to T cells in the absence of sufficient 
CD80/CD86 stimulation of CD28 molecules on T cells. Furthermore, induction of Treg 
cell differentiation takes place as a result of low or no signal through the CD28 receptor 
(28).  
6.3.4.1.  Mechanisms of Tolerance Induction 
Different immunosuppressive mechanisms have been proposed by which tol-
DCs contribute to the induction and maintenance of immune tolerance are described 
below (4,27): 
P The low expression of MHC molecules and co-stimulatory molecules on the surface 
of DCs makes it impossible to stimulate cells effectively, resulting in T cells anergy, 
with regulatory capacity.  
P Secretion of the anti-inflammatory cytokine IL-10, TGF-β or retinoic acid is involved 
in Treg cells and Tr1 induction and inhibition of effector T cells function.   
P Expression of IL-1 related receptor plays an important role in maintaining low levels 
of co-stimulatory molecules and regulating the Treg cells expansion.  
P Expression of immune- modulatory/-inhibitory molecules like PD-L1/2, CTLA-4 
and Ig-like transcripts-3/4 (ILT-3/4) or expression of death receptors like TNF-
Related Apoptosis-Inducing Ligand (TRAIL) or FAS represent ways to inhibit 
efficient responses of T cells. 
P Deprivation of nutritional factors through the expression of indoleamine 2,3-
dioxygenase (IDO) and heme oxygenase-1 (HO-1), with an inefficient antigen 
presentation, leads to a reduction of T cells proliferation and Treg cells induction, 
respectively.   
Antigen-Specific Therapy with Tol-DC for MS | Paula Vargas Durán 
 - 14 - 
P Following a similar mechanism to the previous one, soluble CD25 shedding involves 
IL-2 deprivation and the consequent reduction of T cells proliferation.  
It has been demonstrated that from peripheral CD4+CD25- Foxp3- T cells exposed to 
antigen in the presence of TGF-β and IL-10, without IL-6 or IL1-β, at steady state, 
peripheral Treg cells increase, which promotes the upregulation of Foxp3. (32)  
Recent research has shown that upregulation of C-lectin receptor-2 (CLEC-2) is 
associated with Treg induction. Furthermore, platelet growth factor impulses the 
secretion of IL-10 by DCs, which leads to the consequent induction of Treg cells. (33)  
 
 
6.4. Experimental Autoimmune Encephalomyelitis (EAE): A Model of MS  
 
The use of animals has been very useful to understand the pathophysiology of 
MS. One of the most commonly used animal models to represent MS in rats and mice 
is the experimental autoimmune encephalomyelitis (EAE). The EAE model has allowed 
to discover the most effective treatments and/or beneficial effects they have on them. 
However, in some studied treatments beneficial effects have been observed in EAE that 
have not been generalized in MS, in some cases even leading to a worsening of disease 
indices. Nonetheless, most of the immunological processes first determined in EAE are 
directly adaptable to MS. (4,34)  
Figure 6. Different immunosuppressive mechanisms of tolerogenic dendritic cells (tol-DCs) (27).   
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The EAE animal model has been able to demonstrate the participation of CD11b+ and 
CD11c+ DCs in both Treg and Tr1 cells generation (35). Therefore, one of the key 
mechanisms to induce antigenic tolerance is the stimulation of DCs with a regulatory 
profile (4). 
Other researchers have made comparisons regarding the use of oral immunosuppressive 
drugs (e.g., Vitamin D3) during days before and days after induction of EAE in animals. 
The results obtained were similar in both: an increase in CD4+Foxp3+ Treg cells, an 
increase in IL-10 levels in lymph nodes of treated animals and a significant 
improvement in clinical severity. These suggest that the main target of the tolerogenic 
effect of vitamin D3 are DCs.  Other projects indicate that in DCs absence during the 
priming process of autoreactive T cells leads to a deficiency of cell generation that, 
which ultimately results in a violent attack against the CNS. (26,35,36)  
6.5. Antigen-specific therapy in MS 
The exploration of immune-tolerogenic therapies to treat autoimmune disease 
such as MS is justified by the need to find more selective therapies designed to 
restructure tolerance itself without causing general immunosuppression. Currently, 
common treatment options are life-long systematic immune suppression, which can 
cause serious side effects such as opportunistic infections, secondary autoimmunity and 
increased risk of malignant tumors. (4,25,27) 
Antigen-specific immunotherapy has several advantages. These include the ability to 
restructure, enhance, or induce peripheral immune tolerance for pathogenic adaptive 
response of T and B cells without reducing overall immune surveillance against 
microbes or tumors (37). Furthermore, it is a highly selective approach, which should 
lead to high safety and efficacy in immunotherapies (38).  
Focusing on the MS, the specific target antigen is undiscovered yet, however, it is 
known that the proteins in the myelin sheath, such as myelin peptides of myelin basic 
protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein 
(PLP) are important targets in the autoreactive immune response. Several myelin 
immunodominant peptides from MS patients have been identified ex vivo, to develop 
antigen-specific tolerance for MS. These peptides have been tested in clinical trials 
using autologous leukocytes chemically coupled with these peptides. (38,39) 
6.6.   Generation of Tol-DC in vitro 
In recent years, many protocols to generate stable human monocyte-derived tol-
DCs in vitro have been established. Many of those are based on monocytes (CD14+) as 
precursor cells of DCs due to the high number of cells obtained in peripheral blood. (25) 
DCs can be produced in vitro from monocyte cultured with IL-4 and GM-CSF, which 
promote differentiation and growth. DCs can become tol-DCs when their regulatory 
phenotype is induced with anti-inflammatory cytokines like IL-10 or TGF-β, 
immunosuppressive drugs like vitamin D3, estriol, corticosteroids (dexamethasone) or 
rapamycin (see Figure 7 (40)). Then, to boost peptide-specific properties to tol-DCs, 
Antigen-Specific Therapy with Tol-DC for MS | Paula Vargas Durán 
 - 16 - 
they are cultured with a defined maturation cytokine cocktail like prostaglandin E2, IL-
1β, TNF-α, IL-6 or lipopolysaccharide (LPS) activation (4,25,27,38). Lastly, to achieve 
efficient clinical responsiveness following tol-DCs administration, tol-DCs require 
pulsing with relevant antigens e.g., myelin peptides in MS (28). The tol-DCs generation 
process must comply with good manufacturing practice (GMP) conditions (38).  
 
According to some studies, tol-DCs generated with dexamethasone and other stimuli 
have a stable phenotype, intermediate expression of co-stimulatory molecules CD80 and 
CD86, low expression of CD40, secrete high amounts of IL-10 and TGF-β (anti-
inflammatory cytokines) and low amounts of IL-12, IL-23 and TNF-α (pro-
inflammatory cytokines). (4) 
In a clinical trial conducted in patients with Crohn’s disease, it was observed that 
intraperitoneal administration of dexamethasone/vitamin D3-treated tol-DCs had low 
expression of CD1a and CD14, and high expression of CD209, which has been 
associated with an increase in Treg cells, so a clinical improvement in some patients 
(38,41). Regarding to tol-DCs migration in vivo, researches conducted so far have not 
been able to determinate tol-DCs can reach the inflamed CNS. However, recent data 
suggest that tol-DCs shuttle across the BBB could be facilitated by the introduction of 
de novo CCR5 expression using mRNA electroporation into tol-DCs (28,38).  
It is important to highlight that a crucial part in the generation of tol-DCs is that they 
must have particular characteristics after culture (42):  
P Low expression of co-stimulatory molecules. 
P High stability after maturation stimuli and its production of IL-10. 
P Low activation of T cells. 
Nonetheless, the generation of tol-DCs in vitro has different disadvantages, such as 
patient-specific, high cost and laborious. To overcome these limitations, other 
approaches have been conducted to establish tol-DCs in vivo. One possible approach, 
among several others, is exploit coadministration of free autoantigens or autoantigens 
encapsulated with nanoparticles, microparticles or liposomes, carrying tolerogenic 
factors that are released specifically to DCs. (28) 
Figure 7. Generation of tolerogenic dendritic cells in vitro. Adapted from: Yoo et al. (40). 
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Xie et al. (26).  has provided the appropriate information to make below sections (6.6.1., 
6.6.2. and 6.6.3.). 
6.6.1.  How Does Estrogens Induce the Regulatory Phenotype of Tol-DCs?  
Estrogens (e.g., estriol) play a beneficial role in the pathogenesis of MS since 
the incidence of relapses is lower in pregnant patients with MS. Estrogen-treated mature 
DCs had inhibited pro-inflammatory cytokine secretion in vitro and presented a low 
ability to present antigens. Reduction in both Th1 and Th2 cytokine production and 
inhibition of T cell responses occur when estrogen-activated DCs induce IDO expression. 
In MS patients, estrogen upregulated IDO expression on DCs and inhibited Th1 and Th2 
cytokine secretion. However, estrogen is not commonly used clinically due to its side 
effects, although there is evidence estrogen can relieve the MS symptoms and reduce 
relapses incidence. 
Figure 8. Differentiation of monocyte-derived immunologic and tolerogenic DCs. DCs differentiate 
from monocytes into iDCs in the presence of IL-4 and GM-CSF. In the presence of maturation signals 
(pro-inflammatory cytokines), DCs are activated and acquire a stimulatory phenotype, which they 
induce effector/cytotoxic T responses. Differently, in the absence of maturation factors, the incubation 
of iDCs with anti-inflammatory mediators or genetic modification of DCs can lead to the generation of 
tol-DCs, which promote anergy, apoptosis or activation of Treg cells. VIP: Vasoactive Intestinal 
Peptide; TSLP: Thymic Stromal Lymphoietin. (28) 
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6.6.2. How Does Vitamin D3 Induce the Regulatory Phenotype of Tol-DCs?   
 
As discussed in the introduction, sun exposure deficiency increases the risk of 
MS, that is, vitamin D deficiency is a risk factor for MS (5). Vitamin D levels in MS 
patients are lower than in healthy individuals. Similarly, vitamin D levels in MS patients 
who are in relapse are lower than those during remission states.  
 
Vitamin D plays an immunomodulatory role when it interacts with vitamin D receptor 
(VDR), which is expressed in lymphocytes. 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) is 
the active form of vitamin D in vivo. In vitro, 1,25(OH)2D3 inhibits the proliferation of 
MBP-specific T cells and increases Treg cells from MS patients. In addition, in vitro, 
1,25(OH)2D3 can partially block monocyte differentiation, directed by GM-CSF and IL-
4, in DCs. When PBMCs, in the presence of GM-CSF and IL-4 in vitro, differentiated 
into DCs and were treated with 1,25(OH)2D3, their ability to mature APCs was inhibited. 
Likewise, when monocyte-derived DCs from RRMS patients were treated with 
1,25(OH)2D3, DCs were characterized by an immature phenotype, inhibited IL-12p40 
secretion, and increased chemokine C-C ligand-2 (CCL2) secretion.  
 
Tol-DCs induced by1,25(OH)2D3 and stimulated with myelin peptides led to stable 
antigen-specific hyporesponsiveness in myelin-reactive T cells from patients with 
RRMS. Furthermore, a significant increase in IDO expression was shown with vitamin 
D-induced tol-DCs. All of these studies revealed that vitamin D-induced tol-DCs have 




6.6.3.  What Role Do Each of the Cytokines Play in the Generation of Tol-DCs in vitro?   
Protocol generation of tol-DCs in vitro requires the representation of a set of 
cytokines. Each of them with a specific function.  
First, monocytes isolated from PBMCs pool are culture with cytokines to induce 
differentiation to DCs with immature phenotype:   
§ GM-CSF: GM-CSF is a cytokine required for Th17 to become pathogenic T cells 
(differentiation) and promote DCs maturation. A study has demonstrated that 
autoreactive helper T cells with normal IL-17 or IFN-γ expression, but 
specifically lacking GM-CSF in mice, failed to induce EAE. Whereas those 
autoreactive helper T cells without IL-17 or IFN-γ expression, but that secreted 
GM-CSF was sufficient to induce EAE. 
 
§ IL-4: IL-4 is a cytokine with potent anti-inflammatory properties. IL-4 therapy 
has been achieved protection from EAE and MS, and a more severe form of 
clinical disease has developed in IL-4 deficient mice. (43) 
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Second, iDCs pass into tol-DCs by adding cytokines, in culture, that impose the 
regulatory phenotype (anti-inflammatory cytokines): 
§ IL-10: IL-10 can inhibit immune responses and induce immune tolerance as it 
can inhibit Th1 cells and induce Tr1 cells. These cells are essential in peripheral 
immune tolerance. IL-10 suppresses the autoimmune response by inhibiting self-
antigen-specific T cell and induces Treg cells, thus playing a beneficial role in 
MS. In vitro, monocyte-derived DCs obtained from MS individuals and treated 
with IL-10 induced the production of IL-4 and IL-10 by autologous lymphocytes, 
whereas cDCs derived from patients with MS and exposed to IL-10 became 
resistant to LPS maturation. Besides, IL-10-treated DCs expressed a low level of 
IL-12 and were unable to stimulate T cell proliferation both in vitro and in vitro. 
 
§ TGF-β: TGF-β is an anti-inflammatory cytokine. DCs treated with TGF-β were 
characterized by immature or tolerogenic phenotype, with less ability to stimulate 
T cells. Therefore, TGF-β-treated DCs have been shown to be potentially 
therapeutic in EAE rats.  
Third, tol-DCs are cultivated in the presence of a define cytokine cocktail in order to 
boost their tolerogenic properties (4,26): 
§ TNF-α: two types of TNF-α are distinguished: membrane-bound TNF-α (mTNF-
α) and soluble form of TNF-α. TNF receptor-1 (TNFR1) is widely expressed and 
binds to both types of TNF, while TNF receptor-2 (TNFR2) is expressed on 
lymphocytes and binds to soluble mTNF-α. TNF-α is a pro-inflammatory 
cytokine, so mice treated with antibodies against TNF-α were resistant to EAE. 
Those mice deficient in TNFR1 or TNFR1/TNFR2 are also resistant to EAE, 
while severe EAE symptoms were exhibited in TNFR2 deficient mice. These 
findings suggest that TNFR2-linked mTNF-α signal has a protective role. This 
protection role could justify the reason that patients treated with anti-TNF-α agent 
aggravated the disease in a clinical trial. 
 
§ IL-1β: studies reveal that a significant reduction in disease severity during EAE 
was observed in those IL-1β receptor knock-out mice. IL-1β receptor knock-out 
mice leads to a significant decrease in VCAM-1 expression and, consequently, a 
decrease in leukocytes infiltration in the spinal cord in rodents exposed to EAE. 
Elevated levels of IL-1β were found in brain lesions of MS subjects. 
 
§ IL-6: IL-6 is a pro-inflammatory cytokine and, along with TNF-β, promotes Th17 
differentiation. IL-6-knock-out mice are completely resistant to EAE induction. 
Furthermore, mice that have the IL-6 receptor blocked, through inhibition of Th17 
differentiation, prevent the EAE induction.  Researchers have found DCs are the 
key cells required to produce IL-6 and boost EAE. Finally, IL-6 was found in the 
brain of MS individuals. 
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6.7. Clinical trial with Tol-DCs 
Recently, Zubizarreta and her colleagues developed a phase Ib clinical trial in 
which they included eight patients with MS to test increasing concentrations of 
autologous tol-DCs loaded with various peptides of myelin proteins. The main objective 
of the trial was to assess safety and tolerability, while the secondary objective was to 












6.7.1.  How Was the Clinical Trial Conducted?  
 
Autologous monocyte-derived DCs were obtained from the patients by 
leukapheresis (procedure to separate and collect monocytes from the blood (44)). 
Monocytes were cultured in the presence of IL-4 and GM-CSF to accomplish the 
differentiation process, anti-inflammatory cytokines and dexamethasone to induce 
tolerogenic phenotype. Then, a mixture of cytokines was added including IL-1β, IL-6, 
TNF-α and prostaglandin E2 as well as immunogenic peptides in order to increase the 
tolerogenic properties of peptide-specific DCs. DCs were stimulated with myelin peptides 
from MBP, PLP and MOG. Finally, tol-DCs were progressively administered by IV 
injection in increasing doses (38). Since the cells are from the patients himself 
(autologous), they do not suffer rejection and can perform their function after being 
injected (9). 
 
Figure 9. Tolerogenic dendritic cells (DCs) 
in clinical application. For clinical 
applications, CD14+ monocytes are isolated 
from apheresis products to generate 
tolerogenic DCs, which are loaded with 
(auto-)antigens. Subsequently, antigen-
specific tolerogenic DCs are reinjected into 
the patients to affect the inflammatory 
immune response of autoimmune disease. 
(27)  
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6.7.2. Results and Conclusion of the Clinical Trial  
They obtained the following results (38): 
- Safety: tol-DCs therapy was well tolerated, with no serious side effects or therapy-
related adverse reactions. 
- Efficacy and clinical monitoring: patients remained clinically stable in terms of 
relapse, disability and various measurements with MRI.  
- Immunological responses: a significant increase in the production of IL-10 
levels was observed in peptide-stimulated PBMC, as well as an upward trend in 
the frequency of a subtype of Treg cells, Tr1 (CD4+ IL-10+) and a significant 
decrease in memory CD8+ and NK cells. 
 
Evidence was obtained that tol-DCs therapy induces peptide-specific tolerance by 
promoting T cells adaptive regulatory function. Therefore, as individuals with MS are 
considered to have decrease Tr1 cells function, increasing Tr1 cells function by tol-DCs 
could contribute to restructuring peripheral immune tolerance in patients with 
autoimmune disease.  As the trial was not developed to evaluate efficacy at the clinical 
level, no conclusions should be drawn in terms of efficacy, but future trials with the power 
to show clinical efficacy (phase II and/or phase III clinical trials, including control 
(placebo) group) will be able to demonstrate whether the increase in Tr1 cells response 
can actually modify MS course. With these results, they conclude that IV administration 
of myelin peptide-loaded DCs is safe and feasible without remarkable side effects and 
showing a promising immunological and clinical results. (4,38) 
 
6.8.  Overview of Tolerance-Inducing Therapeutic Approaches for MS 
 
After the discovery of the myelin proteins (MBP, MOG and PLP) as a critical target 
of the autoreactive immune response in parallel ways to the generation of tol-DCs 
approach as a therapeutic tool, several investigations were launched with the same 
purpose: inducing antigen-specific tolerance in MS. (4,45) 
 
Three main branches are identified within the tolerance-inducing therapeutic approaches 
that entered the clinical phase in MS: 
 
6.8.1. Peptide-Based Tolerance-Inducing Vaccination  
 
1. Transdermal administration of MOG, MBP, PLP peptides: induction of 
immunological tolerance was demonstrated by activation of LCs and 
subsequent induction of IL-10 secreted by T cell. Immunological effects 
resulted in a significant reduction in annualized relapse rate and lesion activity 
on MRI (measurements of disease). (46,47) 
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2. Subcutaneous administration of altered peptide ligand (APL): clinical trial 
consisted of incorporating amino-acids substitutions at TCR contact positions. 
Exacerbations of the disease were demonstrated following treatment, which is 
why the trial was halted. (48) 
 
3. Intradermal administration of apitopes (AXT-MS-1467): a technique that 
consists of designing synthetic soluble peptides that mimic the naturally 
processed epitopes, also called apitopes. These apitopes induce antigen-
specific expansion of Treg cells, capable of “switching off” pathogenic T cells 
responsible for myelin damage in the CNS. Two clinical trials have been 
carried out with the ATX-MS-1467 apitope (a mix of four short peptides from 
MBP) in which no serious treatment-related adverse effects. A reduction in 
brain lesions observed by MRI was also revealed. (49,50) 
 
4. Subcutaneous administration of mannosylated liposomes containing MBP 
peptides: another alternative is to reach MBP peptides to APCs in vivo for 
natural processing, presentation in a tolerogenic environment, and involving 
antigen-specific T cells. This process is allowed by determining specific 
markers expressed on the surface of APCs, such as CD-206 (mannose 
receptor). In this context, encapsulation of selected immunodominant MBP 
peptides into mannosylated liposomes improved the uptake of the peptide, 
through the CD-206 receptor, by DCs. This resulted in immune tolerance to 
myelin-derived antigen. In clinical trials, researchers observed a significant 
reduction in serum levels of CCL2, CCL4, IL-7 and IL-2. (51,52) 
 
5. Both intradermal and intramuscular administration of TCR peptide 
vaccination: this approach consists of administering short amino-acid 
sequences from the TCR-derived of pathogenic T-cell clones, to induce 
immunoregulation mediated by T cell directed to T-cells expressing those 
TCRs. Intradermal injection of synthetic TCR peptides resulted in clinical 
improvement, along with beneficial immunological effects, such as increased 
TCR peptide-specific T cells and reduction of MBP-specific T cells. 
Intramuscular injection of TCR peptide also produced immunoregulatory 
effects. (53) 
 
6.8.2. DNA Vaccination 
 
1. Intramuscular administration of MBP-encoding DNA: BHT-3009 is a 
genetically engineered DNA vaccine that encodes the full-length human 
MBP. The purpose is to restore tolerance to MBP. In the clinical trials done 
so far, a reduction in the brain lesions observed on MRI and a reduction in the 
proliferation of IFN-γ-producing T cells accompanied by a reduction myelin-
specific autoantibody titers in CSF have been observed. (54) 
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6.8.3. Cell-Based Tolerance-Inducing Vaccination  
 
1. Subcutaneous administration of T cells: 
 
a. Irradiated autologous T cells: vaccination consists of autologous MBP-
specific T cells isolated from peripheral blood that are inactivated by 
irradiation. Upon administration of irradiated, autologous MBP- specific 
T-cell clones, an immune response is generated to eliminate other 
pathogenic autoreactive T-cells in the patient circulation without 
affecting the rest of the immune system. Reduced relapse rate, 
stabilization in disease progression, and lesion activity on MRI are 
observed in the trials conducted. (55) 
 
b. Mixture of attenuated myelin-reactive T cells: vaccination consists of 
attenuated myelin reactive T cells selected with multiple peptides derived 
from MBP, PLP and MOG. Promising results were seen in a small 
clinical trial involving RRMS and SPMS patients. (56) 
 
2. Intravenous administration of autologous PBMC chemically coupled with a 
mixture of myelin-derived peptide: after selecting a set of seven 
immunodominant myelin-derived peptides, a trial was conducted in which MS 
patients received a single infusion of autologous PBMC pulsed with these 
seven peptides and chemically fixed. The authors concluded that the antigen-
coupled cells had well-tolerance and a favorable safety profile. (39) 
 
3. Intradermal/Intranodal/Intravenous administration of tol-DC pulsed with 
myelin-derived peptides: to date, IV administration of tol-DCs cells is known 
to be safe and feasible. As commented in the previous section of the work, 
Zubizarreta et al.  observed an increase in IL-10 production and frequency in 
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Mode of action 
 
References 
 Peptide-based tolerance-inducing vaccination 
MOG, MBP, PLP 
peptides 
Phase I/II Transdermal Reduction in ARR; 
reduction in MRI 
measurement of 
disease 
Activation of LCs; 





Halted Subcutaneous 62% increase in number 








Phase IIa Intradermal Safe; 79% decrease in 
lesions at MRI 





Phase I Subcutaneous Safe Decrease of CCL2, 






Phase I Both 
intradermal and 
intramuscular 
Safe Generation of IL-1 
secreting TCR 
peptide-specific T 
cells; reduction of 





Phase II Intramuscular Safe and well-tolerated; 
reduction in number of 
active lesions; decrease 
in clinical relapse rate 
Reduction of IFN-γ-
producing myelin-




in the CSF. 
(54) 




Phase I Subcutaneous Safe and feasible;40% 
reduction in relapse 
rate; stabilization of 
disease progression and 













Phase IIb Subcutaneous Clinical endpoints not 










Phase I Intravenous Safe and feasible; 
stabilization of clinical 
and MRI parameters of 




reactivity in pts 
receiving the 






Phase I Intradermal, 
Intranodal and 
Intravenous 
Safe and feasible.  IV administration 
increase in IL-10 
production and 
frequency of Tr1 
cells.   
(38) 
Table 2. Tolerance-inducing therapeutic approaches that entered the clinic for treatment of multiple sclerosis (45). 
ARR: annualized relapse rate; pts: patients. 
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7. Discussion 
Due to the high prevalence of MS, this disease has been the central focus of several 
investigations in different institutions. One of the objectives that has involved the most 
effort has been finding the ideal strategy to silence precisely those immune responses that 
are impaired in MS.  
Currently, only more than ten commercialized drugs are available, and they are partially 
effective and especially in the initial inflammatory phases. The concern is even greater in 
progressive forms of MS, as to date, there is only one approved drug for PPMS 
(Ocrelizumab). Furthermore, most of the treatments used in MS involve general 
immunosuppression, which leads to numerous side effects (infections and even malignant 
tumors). For these reasons, the search for therapies based on antigen-specific immune 
tolerance aims to control inflammation and delay progression or improve the degree of 
disability, as well as being well-tolerated without altering all immune surveillance.  
Among the diversity of immunological therapeutic tools, DCs have demonstrated their 
great potential due to their functional plasticity and the possibility of their generation in 
vitro. So far, DCs have been investigated in various clinical trials to enhance the immune 
response for cancer or infectious diseases. However, the immunosuppressive potential of 
DCs has been little exploited to treat human autoimmune diseases, organ transplant 
rejection or even allergies.  
Multiple protocols of tol-DCs generation in vitro have been established based on PBMCs. 
In general, these protocols indicate monocytes must be cultured with differentiation and 
growth cytokines to obtain iDCs, subsequently with regulatory cytokines and 
immunosuppressive drugs such as dexamethasone or vitamin D3 to obtain tol-DCs, and 
for boosting their tolerogenic properties, pro-inflammatory cytokines must be added to 
the culture. Finally, these tol-DCs can be loaded with myelin peptides so that specific 
tolerance to these peptides is created and, therefore, does not lead to an autoimmune 
reaction. Although the generation of tol-DCs for clinical application has many positive 
aspects, it should be mentioned that has certain disadvantages, such as that it is very 
laborious, patient-specific or high cost.  
Focusing on the phase Ib clinical trial coordinated by Dr. Benítez and Dr. Villoslada at 
Hospital Clínic, it was decided to generate tol-DCs in vitro using dexamethasone to 
induce the regulatory phenotype, since in a previous study which followed the same 
therapeutic strategy involved patients with Crohn’s disease, was the immunosuppressor 
agent that provided the best results regarding the increase of Treg cells. Although the 
target autoantigens of the myelin sheath are undetected, the target proteins of the myelin 
with which tol-DCs can be loaded and generate a local immunosuppression situation are 
known. The Hospital Clínic research group selected peptides identified in previous 
studies that were recognized by T lymphocytes from patients. However, Dr. Benítez 
points out that it is important to identify even more specific targets on which the T 
lymphocytes focus (See Annex). 
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Several studies using antigen-specific therapy with tol-DCs have proved safe and well-
tolerant, and these also show promising immunological results, mainly for patients with 
RRMS. Returning to the clinical trial phase Ib of the Hospital Clínic, an increase in the 
anti-inflammatory cytokine IL-10 and the Treg cells, Tr1, was observed, which could 
mean a modulation in the immune response and a promote in immune tolerance. 
Therefore, windows are opened to future clinical trials where a control groups (placebo) 
are included and the results obtained would be crucial to correlate clinical efficacy with 
modulation of immunological parameters. To achieve this, previously, it will be 
necessary to determine several parameters are still unknown, such as the definition of the 
optimal route of administration, the dose of cells or the potential tolerogenic effect of 
circulating tol-DCs.  
Although the optimal dose to induce tolerance has yet to be determined, it is intuited that 
to ensure the ability to regulate the autoimmune response is permanent or at least lasts for 
years after the intervention, many repetitive injections with tol-DCs may be required. This 
is so, to maintain the phenotypic and functional properties of tol-DCs.  
Regarding administration route of the therapeutic tolerance-inducing vaccine, it should 
be considered that the different routes lead to different sites of tol-DCs aggregation and 
for the effective induction of tolerance, it is necessary to connect with the autoreactive T 
cells, which take place mainly in the lymph nodes. However, direct injection into the 
lymph nodes is technically very complicated and could damage the lymph node structure. 
Furthermore, an unwanted pro-inflammatory microenvironment could develop from 
tissue damage. Zubizarreta and her colleagues chose IV injection to carry out the clinical 
trial because in a previous study with pulsed tol-DCs in the EAE by IV injection, they 
observed that tol-DCs followed optimal routes in vivo. These cells reached the liver and 
the spleen and in small quantities the lymph nodes, thymus and bone marrow where they 
remain stable for 7 days. Nonetheless, the ability of tol-DCs to migrate to the inflamed 
CNS in MS is undiscovered, migration to primary and secondary lymphoid organs 
propose that tol-DCs could modulate the immune response in these organs and adjust the 
autoimmune attack in the brain. 
Future perspectives on the application of this antigen-specific therapy with autologous 
tol-DCs indicate that could not only be a great advance for MS, but it is expected that it 
could be applied in other autoimmune and rheumatic diseases, such as autoimmune 
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8. Conclusion 
The development of the antigen-specific immunomodulatory strategy with tol-DCs 
is highly promising. However, there are still some obstacles to overcome in order to make 
a firm correlation of clinical effectiveness with modulation of immunological parameters 
and, therefore, to consider the possibility of using tol-DCs as a real treatment for MS. The 
main conclusions to underline of this project are:  
§ In neurodegeneration and axonal atrophy, not only immune mechanisms, in which 
include the participation of microglia and astrocytes, are involved, but also 
mechanisms related to mitochondrial injury, oxidative stress or ionic imbalance. 
§ Multiple protocols in vitro to generate stable human tol-DCs with growth, 
differentiation and regulatory cytokines, among other factors have been 
established, by exhibiting numerous mechanisms to dampen the immune 
response. Vitamin D3 and dexamethasone have shown potential value as an 
immunosuppressive agent.  
§ To date, clinical trials with myelin peptides-loaded tol-DCs have been shown to 
be safe and feasible, besides to promising immunological results.  
§ Phase II and/or III clinical trials are required to provide information on the clinical 
efficacy and effectiveness of tol-DCs in MS patients. For this, it is necessary to 
define the optimal route of administration, the dose of cells and the potential 
tolerogenic effect of circulating tol-DCs.  
§ Among tolerance-inducing therapeutic approaches, the most advanced in terms of 
developmental progress is subcutaneous administration of mixture of attenuated 
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10. Annex: Interview with Dr Daniel Benítez 
Below is a short online interview with Dr. Daniel Benítez, a specialist from the 
Immunotherapy Section of the Immunology Service of the Hospital Clínic-IDIBAPS.  
 
Buenas tardes Dr. Benítez, 
Soy Paula Vargas, estudiante de quinto de Farmacia en la Universidad de Barcelona. 
Estoy realizando el trabajo de fin de grado y está enfocado en uno de los ensayos clínicos 
que usted ha dirigido junto con el Dr. Pablo Villoslada: Células Dendríticas 
tolerogénicas como terapia alternativa para reestructurar el sistema inmune en la 
Esclerosis Múltiple y la Neuromielitis Óptica. Aunque mi trabajo se centra únicamente 
en la Esclerosis Múltiple.  
Me dirijo a usted con el fin de formularle algunas preguntas y obtener algunas 
conclusiones sobre el ensayo clínico realizado en el Hospital Clínic.  
 
1. En el caso de la Esclerosis Múltiple aún se desconocen los auto-antígenos diana 
que derivan en la reacción autoinmune, por tanto, ¿cuál fue el criterio para 
escoger los péptidos de mielina con los que se cargaría la célula dendrítica 
tolerogénica? 
El criterio fue seleccionar péptidos identificados en diferentes estudios previos que 
eran reconocidos por linfocitos T de pacientes. También fueron estos péptidos los 
utilizados en un ensayo clínico por Roland Martin, utilizando células 
mononucleares de sangre periférica inactivadas para generar tolerancia.  
Es cierto que no se conoce el/los antígeno/s pero sí se conoce que la diana es las 
proteínas de la vaina de mielina, con lo que se espera generar una situación de 
inmunosupresión local. Pero tienes razón de que es importante identificar dianas 
más específicas, centradas en los linfocitos T. 
 
2. El hecho de utilizar citoquinas como GM-CSF y IL-4 para promover el 
crecimiento y la diferenciación de los monocitos obtenidos de sangre periférica y 
dexametasona como agente inmunosupresor, ¿fue un protocolo establecido que 
se siguió en anteriores ensayos? ¿cómo sabían que estos agentes eran los más 
adecuados en cuanto a estabilidad para la generación de células dendríticas 
tolerogénicas? 
Existen diferentes protocolos de generación de células dendríticas tolerogénicas, 
básicamente con dexametasona, con vitamina D3, combinación, o bien utilizando 
IL-10, a parte de otros. Nosotros pusimos a punto el protocolo utilizando 
dexametasona en el laboratorio, y es el que mejor nos funcionó mirando en   
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conjunto todos los parámetros. Esas mismas células las habíamos aplicado en 
pacientes con enfermedad de Crohn, con buenos resultados. 
 
3. ¿Cuál fue el criterio seguido para escoger a los pacientes de Esclerosis múltiple 
que se incluirían en el ensayo? ¿Se considera que este tratamiento celular podría 
ser adecuado tanto para pacientes en estados iniciales inflamatorios como en 
estados más avanzados con formas progresivas?    
No hubo ningún criterio para seleccionar a los pacientes, más allá de criterios de 
inclusión/exclusión clínicos, al ser una fase I, se ha de demostrar seguridad en la 
población en general. En siguientes etapas del ensayo se puede ir a un grupo 
concreto de pacientes.  
Está claro que no todos los pacientes se pueden beneficiar de esta terapia y que 
quizás aquellos con una enfermedad más inflamatoria, se puedan beneficiar más 
que los que tienen formas progresivas. Pero esto es algo que está por demostrar. 
 
4. ¿Cómo averiguaron la dosis exacta de células dendríticas que deberían de 
inyectar vía intravenosa a los pacientes después de que éstas fueran tratadas para 
convertirlas en tolerogénicas a péptidos de mielina? 
No está establecida cual es la dosis de células adecuadas. Nosotros hicimos el 
estudio con 4 dosis posibles, para intentar establecer una dosis segura y que fuera 
posible generar para los pacientes. 
 
5. Como he leído en el ensayo, los resultados obtenidos son prometedores y abren 
puertas a futuros ensayos con células dendríticas tolerogénicas que incluyan más 
pacientes. ¿Conoce si actualmente si hay algún ensayo de fase II que se esté 
desarrollando y si está resultando una terapia eficaz, tolerable y segura para los 
pacientes? 
Nosotros en pocos meses vamos a empezar un ensayo en fase II, estamos 
trabajando en la documentación y aprobación por las agencias reguladoras. Hay 
también otros ensayos a nivel europeo, pero no son fase II con brazo control. 
 
Agradezco su colaboración con el trabajo, 
Paula Vargas Durán 
 
 
